FDA Approval of Gamifant® (emapalumab-Iszg) for Primary HLH Treatment

Dr. Carol Satler discusses the recent (Nov 2018) FDA approval of Gamifant® (emapalumab-lzsg), the first and only treatment indicated for primary hemophagocytic lymphohistiocytosis (HLH). Gamifant®is a product of Sobi, an international bio-pharmaceutical company dedicated to rare diseases.

Carol Satler, M.D., Ph.D., joined Sobi as Vice President of Medical Affairs in North America in October 2018. She has more than 25 years of experience in the healthcare industry spanning roles in medical affairs, clinical research and clinical practice as a pediatrician and pediatric cardiologist. She most recently served as the Vice President & Therapeutic Area Head, Cardiovascular Clinical Research at Gilead Sciences, Inc., where she worked on clinical development and launch planning for multiple rare disease products. Prior to that she was Vice President of U.S. Medical Affairs, General Medicine at Bayer Healthcare Pharmaceuticals, Inc.; and Vice President and Head, North America Medical Affairs at UCB, Inc. She previously held medical and clinical roles at Millennium Pharmaceuticals, Inc.; Forest Research Institute, Inc.; Sanofi; and Pfizer, Inc.; and she served as President and Chief Executive Officer at Indigo Pharmaceuticals, Inc. Satler trained and served on the faculty at Harvard Medical School and Boston Children’s Hospital in Medicine, Pediatrics and Pediatric Cardiology for over a decade. She earned her M.D.-Ph.D. from Case Western Reserve University and her B.A. in Chemistry from Wesleyan University.